




Descriptive Analysis of Folate Supplementation Patterns and RBC Folate Levels in Women of Reproductive Age in a Brazilian Hospital

Marília Körbes Rockenbach^{1,2}, Jéssica de Menezes^{1,2}, Lailson Navarro^{1,2}, Fabyanne de Oliveira^{1,2}, Lavínia Schüler-Faccini^{1,2}, Maria Teresa Vieira Sanseverino^{1,2}, and Thayne Woycinck Kowalski^{1,2}

1 Universidade Federal do Rio Grande do Sul (UFRGS); 2 Hospital de Clínicas de Porto Alegre (HCPA)

Introduction

Periconceptional folic acid supplementation
0.4 mg/day or 4 mg/day (presence of risk factors)



Neural tube defect (NTD)
prevention



Excessive intake and alternative
formulations are controversial



Brazil's public health system (SUS)
distributes folic acid at 5 mg dose


Aim: to evaluate folate supplementation patterns
and status in women attending in the Hospital de
Clínicas de Porto Alegre (HCPA)

Methods



Ethics approval
(CAAE: 79644924.0.0000.5327)

Pregnant and childbearing age women
Observational study



Consent form
Questionnaire



Red blood cell (RBC)
folate assesment



DNA and RNA
extraction

Results

Table 1: Participant's characteristics

Pregnant women		
Yes	3 (10.3%)	34 (72.3%)
No	29 (89.7%)	13 (27.7%)
Age (years)	33.5 (31-34)	31 (27-35)
Body mass index (kg/m²)	29.24 (24.59-33.44)	28.15 (24.07-33.41)
RBC Folate (ng/mL)	792.5 (670.5-946.25)	1130 (959.5-1237.5)
Daily folate intake (µg)	275.85 (177.78-412.84)	343.17 (268.07-438.33)
Alcohol consumption		
Yes	14 (43.8%)	4 (8.5%)
No	18 (56.2%)	43 (91.5%)
Tobacco		
Yes	2 (6.2%)	2 (4.2%)
No	30 (93.8%)	45 (95.8%)
Education		
High school or lower	13 (40.6%)	24 (51%)
Higher education	19 (59.4%)	23 (49%)
Ethnic-racial self-declaration		
Black	4 (12.5%)	4 (8.5%)
Brown	4 (12.5%)	9 (19.2%)
White	23 (71.9%)	34 (72.3%)
Indigenous	1 (3.1%)	0

Median supplementation period
159.5 days (119.25-245.25)

Graph 1: Distribution of patients according to folate formulation




Table 2: Supplementation dose and folate status

Dose	Median RBC folate (ng/mL)
Low (N = 17)	1061 (955-1220)
High (N =16)	1252.5 (953.75-1910.75)
Diverse (N=12)	1138 (968.5-1203)

The results are presented as median (IQR) or number (%). RBC folate reference values: 523 ng/mL – 1257 ng/mL. Low dose (0.1-0.8 mg/day); High (≥ 5 mg/day); Diverse (alternative or combined doses).

Acknowledgments



Conclusion: Folic acid is the only folate formulation proven effective for NTD prevention, yet 38.3% of patients used alternative formulations, emphasizing the need for clearer public policies and stronger evidence regarding alternative regimens. Although median folate status was adequate regardless of supplementation dose, some patients presented values above the reference range, underscoring the importance of monitoring high doses and potential excess. Future perspectives include investigating genetic polymorphisms and DNA methylation patterns.